Rbo & Co Decreased Its Abbott Labs (ABT) Stake; Conversion Services International (CSII)’s Sentiment Is 1.13

Abbott Laboratories (NYSE:ABT) Logo

Conversion Services International Inc (CSII) investors sentiment decreased to 1.13 in 2018 Q2. It’s down -0.14, from 1.27 in 2018Q1. The ratio fall, as 62 institutional investors increased and started new stock positions, while 49 sold and decreased stock positions in Conversion Services International Inc. The institutional investors in our database now hold: 27.95 million shares, up from 26.24 million shares in 2018Q1. Also, the number of institutional investors holding Conversion Services International Inc in top ten stock positions increased from 0 to 1 for an increase of 1. Sold All: 10 Reduced: 39 Increased: 39 New Position: 23.

Rbo & Co Llc decreased Abbott Labs (ABT) stake by 6.09% reported in 2018Q2 SEC filing. Rbo & Co Llc sold 15,277 shares as Abbott Labs (ABT)’s stock rose 6.93%. The Rbo & Co Llc holds 235,437 shares with $14.36M value, down from 250,714 last quarter. Abbott Labs now has $122.86B valuation. The stock decreased 2.22% or $1.59 during the last trading session, reaching $69.95. About 7.95M shares traded or 16.84% up from the average. Abbott Laboratories (NYSE:ABT) has risen 28.17% since December 8, 2017 and is uptrending. It has outperformed by 12.55% the S&P500. Some Historical ABT News: 18/05/2018 – ABBOTT: WORKING TO ENSURE CRIME IS PROSECUTED APPROPRIATELY; 18/04/2018 – Abbott Labs Sees 2Q EPS Cont Ops 33c-35c; 18/04/2018 – Abbott’s quarterly profit, sales beat Street estimates; 23/05/2018 – ABBOTT GETS FDA OK FOR XIENCE SIERRA HEART STENT; 18/04/2018 – Abbott Labs Sees FY Cont Ops EPS $1.23-$1.33; 28/03/2018 – Abbott has invested an undisclosed amount in Bigfoot Biomedical, a start-up creating diabetes care devices and systems; 23/05/2018 – Abbott Labs: Tendyne Shows Significant Reduction of Mitral Regurgitation Symptoms and Low Mortality Rates; 19/03/2018 – Abbott’s MitraClip Therapy Receives National Reimbursement in Japan to Treat Patients with Mitral Regurgitation; 18/05/2018 – Texas Gov. Abbott: Suspected Shooter Has No Criminal History; 29/03/2018 – Cardiovascular: Abbott Initiates Trial to Evaluate Improved Survival And Outcomes with the CardioMEMS Monitor

First Light Asset Management Llc holds 2.45% of its portfolio in Cardiovascular Systems, Inc. for 487,207 shares. Perkins Capital Management Inc owns 68,350 shares or 1.58% of their US portfolio. Moreover, Ironwood Investment Management Llc has 1.26% invested in the company for 54,896 shares. The Wisconsin-based Cortina Asset Management Llc has invested 1.24% in the stock. Brown Capital Management Llc, a Maryland-based fund reported 2.79 million shares.

Analysts await Cardiovascular Systems, Inc. (NASDAQ:CSII) to report earnings on February, 6. They expect $-0.04 EPS, down 300.00% or $0.03 from last year’s $-0.01 per share. After $-0.09 actual EPS reported by Cardiovascular Systems, Inc. for the previous quarter, Wall Street now forecasts -55.56% EPS growth.

More notable recent Cardiovascular Systems, Inc. (NASDAQ:CSII) news were published by: Globenewswire.com which released: “Analysis: Positioning to Benefit within Cardiovascular, Ennis, Sparton, LightPath Technologies, Blue Apron, and HFF — Research Highlights Growth, Revenue, and Consolidated Results – GlobeNewswire” on November 28, 2018, also Seekingalpha.com with their article: “Premarket analyst action – healthcare – Seeking Alpha” published on August 22, 2018, Seekingalpha.com published: “Cardiovascular Systems gets two-notch upgrade at BAML – Seeking Alpha” on June 27, 2018. More interesting news about Cardiovascular Systems, Inc. (NASDAQ:CSII) were released by: Nasdaq.com and their article: “Cardiovascular Systems’ (CSII) Q1 Loss Wider Than Expected – Nasdaq” published on October 31, 2018 as well as Seekingalpha.com‘s news article titled: “Cardiovascular Systems (CSII) Presents At Leerink Partners 7th Annual Global Healthcare Conference – Slideshow – Seeking Alpha” with publication date: February 15, 2018.

The stock decreased 3.22% or $0.95 during the last trading session, reaching $28.56. About 154,430 shares traded. Cardiovascular Systems, Inc. (CSII) has risen 27.95% since December 8, 2017 and is uptrending. It has outperformed by 12.33% the S&P500. Some Historical CSII News: 09/05/2018 – Global Cardiovascular Drug Delivery Research Report 2018 – Technologies, Markets and Companies 2017-2027 – ResearchAndMarkets.com; 15/05/2018 – Camber Capital Management Buys 3.7% of Cardiovascular Systems; 06/03/2018 – 4C Medical’s Transcatheter Mitral Valve Technology Receives First Place in Cardiovascular Research Technologies 2018 Competition; 26/04/2018 – ClinicalTrial US: Cardiovascular Diseases in Elderly Asthma; 23/04/2018 – cardiovascular systems inc. | viperwire advance guide wire, stealth 36 | K180416 | 04/17/2018 |; 20/04/2018 – FDA: Terumo Cardiovascular Systems Corporation- Flowmeter Module (accessory to Terumo Advanced Perfusion System 1). Provides th; 20/04/2018 – ClinicalTrial US: School-based Behavioural Intervention to Face Obesity and Promote Cardiovascular Health Among Spanish; 26/03/2018 – ClinicalTrial US: Prevention of Cardiovascular Stiffening With Aging and Hypertensive Heart Disease (LVH); 21/04/2018 – DJ Cardiovascular Systems Inc, Inst Holders, 1Q 2018 (CSII); 06/03/2018 – Medscape Partners with the American College of Cardiology to Improve Prevention, Treatment of Cardiovascular Disease

Cardiovascular Systems, Inc., a medical technology company, develops, makes, and markets devices to treat vascular diseases in the United States. The company has market cap of $991.07 million. The firm offers peripheral arterial disease products, including Diamondback 360 Peripheral Orbital Atherectomy System , Diamondback 360 60cm Peripheral OAS, Diamondback 360 4 French 1.25 Peripheral OAS, Diamondback 360 1.50 Peripheral OAS, Diamondback 360 2.00 Peripheral OAS, and Stealth 360 Peripheral OAS, which are catheter platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives. It has a 1503.16 P/E ratio. It also provides Diamondback 360 Coronary OAS, an atherectomy device for the treatment of calcified coronary arteries.

Among 10 analysts covering Abbott Laboratories (NYSE:ABT), 10 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Abbott Laboratories had 11 analyst reports since June 27, 2018 according to SRatingsIntel. The rating was maintained by Raymond James with “Outperform” on Monday, September 24. The stock has “Overweight” rating by Morgan Stanley on Thursday, October 11. On Friday, November 30 the stock rating was upgraded by Goldman Sachs to “Buy”. The stock has “Buy” rating by Stifel Nicolaus on Thursday, July 19. The firm has “Overweight” rating by JP Morgan given on Monday, October 8. The firm has “Outperform” rating given on Thursday, October 18 by Raymond James. The firm earned “Outperform” rating on Monday, September 24 by Wells Fargo.

More notable recent Abbott Laboratories (NYSE:ABT) news were published by: Seekingalpha.com which released: “FDA to reboot 510(k) process for devices – Seeking Alpha” on November 26, 2018, also Nasdaq.com with their article: “AbbVie Stock Could Become a New Happy Pill for Investors – Nasdaq” published on December 03, 2018, Seekingalpha.com published: “Medtronic slips 2% premarket on device injuries – Seeking Alpha” on November 26, 2018. More interesting news about Abbott Laboratories (NYSE:ABT) were released by: Forbes.com and their article: “Expect Diagnostics And Medical Devices Business To Drive Abbott’s Near-Term Earnings Growth – Forbes” published on November 28, 2018 as well as Fool.com‘s news article titled: “Stock Market Power Rankings: Microsoft Parties Like Its 2002 – The Motley Fool” with publication date: December 02, 2018.

Investors sentiment increased to 0.96 in Q2 2018. Its up 0.10, from 0.86 in 2018Q1. It improved, as 41 investors sold ABT shares while 583 reduced holdings. 117 funds opened positions while 420 raised stakes. 1.23 billion shares or 0.63% more from 1.22 billion shares in 2018Q1 were reported. Benin Management Corp holds 37,405 shares. Veritable Lp holds 0.17% or 133,583 shares. Deutsche Retail Bank Ag holds 4.40 million shares or 0.18% of its portfolio. Bokf Na invested 0.38% in Abbott Laboratories (NYSE:ABT). Burney accumulated 53,765 shares or 0.19% of the stock. Texas Yale Capital, Florida-based fund reported 5,435 shares. Northstar Investment Ltd Com stated it has 175,232 shares. Bender Robert Assoc accumulated 11,371 shares. Northern Corporation stated it has 26.21M shares. Rhumbline Advisers invested in 0.39% or 3.17 million shares. Blb&B Advisors Llc reported 72,196 shares. Murphy Capital has 0.21% invested in Abbott Laboratories (NYSE:ABT). Cullinan Associates has 0.07% invested in Abbott Laboratories (NYSE:ABT) for 15,770 shares. Neville Rodie And Shaw has invested 0.42% in Abbott Laboratories (NYSE:ABT). Stadion Money Mgmt Llc has invested 0.05% in Abbott Laboratories (NYSE:ABT).

Cardiovascular Systems, Inc. (NASDAQ:CSII) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.